Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2004 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: November 1, 1999
Last updated: July 23, 2008
Last verified: April 2004

November 1, 1999
July 23, 2008
August 1998
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00003532 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Carcinoma of the Ovary

RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.

PURPOSE: This phase II trial studies the effectiveness of antineoplaston therapy in treating patients who have stage III or stage IV ovarian cancer


  • Study the safety and possible effectiveness of antineoplastons A10 and AS2-1 in patients with incurable stage III or IV ovarian cancer.
  • Describe response to, tolerance to, and side effects of this regimen in this patient population.

OUTLINE: This is an open-label study.

Patients receive gradually escalating doses of antineoplaston A10 and antineoplaston AS2-1 by intravenous injection 6 times daily until the maximum tolerated dose level is reached.

Treatment continues for at least 3 months in the absence of unacceptable toxicity or disease progression. Patients achieving complete response (CR) continue treatment for an additional 8 months after achieving CR.

Tumors are measured every 2 months for 1 year and then every 3 months for 1 year.

PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.

Phase 2
Masking: Open Label
Primary Purpose: Treatment
Ovarian Cancer
  • Drug: antineoplaston A10
  • Drug: antineoplaston AS2-1
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
Not Provided
Not Provided


  • Histologically confirmed stage III or IV epithelial or germ cell ovarian cancer that is unlikely to respond to existing therapy and for which no curative therapy exists
  • Measurable disease by CT scan or MRI



  • 18 and over

Performance status:

  • Karnofsky 60-100%

Life expectancy:

  • At least 2 months


  • WBC at least 2,000/mm^3
  • Platelet count at least 50,000/mm^3


  • Bilirubin no greater than 2.5 mg/dL
  • SGOT/SGPT no greater than 5 times upper limit of normal
  • No hepatic failure


  • Creatinine no greater than 2.5 mg/mL
  • No renal insufficiency
  • No history of renal conditions that contraindicate high dosages of sodium


  • No uncontrolled hypertension
  • No history of congestive heart failure
  • No other cardiovascular conditions that contraindicate high dosages of sodium


  • No serious lung disease (e.g., chronic obstructive pulmonary disease)


  • Not pregnant or nursing
  • Fertile patients must use effective contraception for 4 weeks before, during, and for 4 weeks after study participation
  • No active infection
  • No concurrent serious systemic disease


Biologic therapy:

  • At least 4 weeks since prior immunotherapy and recovered
  • No concurrent immunomodulating agents


  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

Endocrine therapy:

  • Concurrent corticosteroids allowed (e.g., dexamethasone or methylprednisone)


  • At least 8 weeks since prior radiotherapy and recovered


  • Recovered from prior surgery


  • Prior cytodifferentiating agents allowed
  • No prior antineoplaston therapy
  • No other concurrent antineoplastic agents
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
CDR0000066579, BC-OV-2
Not Provided
Not Provided
Not Provided
Not Provided
Burzynski Research Institute
Not Provided
Study Chair: Stanislaw R. Burzynski, MD, PhD Burzynski Research Institute
National Cancer Institute (NCI)
April 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP